Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis

Autor: Sarah J George, Jason L. Johnson, Georgios Kremastiotis, Ishita Handa, Christopher L. Jackson

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Kremastiotis, G, Handa, I, Jackson, C, George, S J & Johnson, J L 2021, ' Disparate Effects of MMP and TIMP Modulation on Coronary Atherosclerosis and Associated Myocardial Fibrosis ', Scientific Reports, vol. 11, 23081 . https://doi.org/10.1038/s41598-021-02508-4
Scientific Reports

Matrix metalloproteinase (MMP) activity is tightly regulated by the endogenous tissue inhibitors (TIMPs), and dysregulated activity contributes to extracellular matrix remodelling. Accordingly, MMP/TIMP balance is associated with atherosclerotic plaq

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94b679814a76b96827ff67b599e465f
https://doaj.org/article/288d6673a46843da91a9610e5948e425

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

Autor: Zoi Kanaki, Georgios Agrogiannis, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios K. Iliodromitis, Georgios Kremastiotis, Apostolos Klinakis, Aimilia Varela, Panagiota-Efstathia Nikolaou, Panagiotis Efentakis, Anastasia E. Konstantinidou, Constantinos H. Davos, Ioanna Andreadou, Efstathios Kastritis, Ioannis P. Trougakos, Eleni-Dimitra Papanagnou, M Tsoumani

Publikováno v: Blood. 133:710-723

Carfilzomib (Cfz), an irreversible proteasome inhibitor licensed for relapsed/refractory myeloma, is associated with cardiotoxicity in humans. We sought to establish the optimal protocol of Cfz-induced cardiac dysfunction, to investigate the underlyi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b38d759c3929f546f313ca321e39fb85
https://doi.org/10.1182/blood-2018-06-858415

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo

Autor: Anastasia E. Konstantinidou, Zoi Kanaki, Constantinos H. Davos, Georgios Kremastiotis, Eftathios Kastritis, Meletios A. Dimopoulos, Evangelos Terpos, M Tsoumani, Georgios Agrogiannis, Ioanna Andreadou, Aimilia Varela, Ioannis P. Trougakos, Efstathios K. Iliodromitis, Panagiotis Efentakis, Eleni-Dimitra Papanagnou, Apostolos Klinakis

Publikováno v: Blood. 132:3214-3214

Introduction: Carfilzomib (Cfz) significantly prolongs progression-free survival in relapsed or refractory multiple myeloma patients, as highlighted in the ENDEAVOR trial. However, Cfz has high incidences of cardiotoxicity and heart failure, leading

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b5b0451afbf5c574b36c8c76987e52af
https://doi.org/10.1182/blood-2018-99-112351